Demethylation of CDKN2A in systemic lupus erythematosus and rheumatoid arthritis: a blood biomarker for diagnosis and assessment of disease activity

ConclusionOur findings demonstrated thatCDKN2A methylation levels in PBMCs of SLE and RA patients could be used as a promising diagnostic biomarker. The significant association between hypomethylation ofCDKN2A promoter and disease activity factors in SLE patients, is suggesting thatCDKN2A hypomethylation could be used as an alternative biomarker for assessment of disease activity.Key Points• Several studies have reported increased expression of CDKN2A in SLE and RA suggesting that it may be involved in the pathogenesis of these disorders.• CDKN2A hypomethylation has been implicated in different autoimmune diseases.• Our findings demonstrated that CDKN2A methylation levels in PBMCs of SLE and RA patients could be used as a promising diagnostic and prognostic biomarker.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research